NEW YORK (GenomeWeb News) – Biomarker technology developer ApoCell has received an investment from Boston-based equity investor Summit Partners, which supports life sciences companies.
The amount of the investment was not disclosed.
ApoCell, which spun out from the University of Texas MD Anderson Cancer Center in 2005 and operates out of Houston, will use the funds to continue developing its technology platforms aimed at using biomarker signatures in oncology, diabetes, molecular diagnostics, and drug development.
Summit said that the ApoCell technology can support the analysis and specimen logistics for preclinical to Phase III trials and other similar projects.
Tom Jennings, managing director with Summit Partners, will join ApoCell's board of directors.